SAPK2, p38 MAPK Inhibitor (SB 202190) (Stress-activated Protein Kinase 2)

SB 202190 is a cell permeable pyridinyl imidazole, which acts as a strong inhibitor of SAPK2a/p38 and SAPK2b/p38beta MAP kinases (IC50=280nM and 350nM, respectively). SB 202190 has no effect on the activity of the Erk or SAPK/JNK MAP kinases and is reported to block LPS induced TNF-a and IL-1beta production in mice. The compound is a slightly better inhibitor than the related compound SB 203580. \n\nSolubility:\nSoluble in DMSO (50mg/ml).\n\nApplications:\nSpecific inhibitor of p38/SAPK2a MAPK and P38b/SAPK2a MAPK activity. Other applications not tested.\n\nProtein Kinase Inhibition Assay:\nWhen pre-incubated for five minutes with 0.2ug of SAPK2a/p38 MAPK or SAPK2b/p38beta MAPK, 1-10uM of SB 202190 will inhibit the activity of these kinases 80-95%. The final concentration of SB 202190 needed may depend on the amount of enzyme used. Optimal dilutions to be determined by the researcher.\n\nStorage and Stability:\nStable for at least 12 months at -20 degrees C in the dark. After reconstitution, aliquot and freeze at -20 degrees C, away from light.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

S0096-25

Size

1mg

Form

Supplied as a pale yellow solid.

Purity

(same/more than) 98% (HPLC)

References

1. Jiang, Y., et al., J. Biol. Chem. 271: 17,920 (1996). 2. Kramer, R.M., et al., J. Biol. Chem. 271: 27,723 (1996). 3. Li, Z., et al., Biochem. Biophys. Res Commun. 228: 334 (1996). 4. Lee, J.C., et al., Nature 372: 739 (1994).